Acute hepatitis B
4Curable or preventable in mostAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.
Milestones
dot size = significance- 1986Interferon alfa-2b approved (FDA)
- 1995Lamivudine approved (FDA)
- 1996Hepatitis b virus hbsag surface protein antigen approved (FDA)
- 2000Hepatitis b virus s protein, pre-s1 protein and pre-s2 protein virus like particles approved (FDA)
- 2001Tenofovir disoproxil approved (FDA)
- 2002Adefovir dipivoxil approved (FDA)
- 2002Peginterferon alfa-2a approved (FDA)
- 2005Entecavir anhydrous approved (FDA)
- 2006Telbivudine approved (FDA)
- 2009Hepatitis b immune globulin approved (FDA)
What's being tested now
Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.
See all 206 active Chronic Hepatitis B trials on Clin2 →